NasdaqCM:CASI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally.


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has CASI Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CASI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-0.8%

CASI

0.07%

US Biotechs

2.9%

US Market


1 Year Return

-13.0%

CASI

23.9%

US Biotechs

8.9%

US Market

Return vs Industry: CASI underperformed the US Biotechs industry which returned 23.9% over the past year.

Return vs Market: CASI underperformed the US Market which returned 8.9% over the past year.


Shareholder returns

CASIIndustryMarket
7 Day-0.8%0.07%2.9%
30 Day57.8%4.8%10.6%
90 Day45.6%10.5%5.1%
1 Year-13.0%-13.0%25.1%23.9%11.4%8.9%
3 Year162.0%162.0%32.9%28.5%34.3%25.4%
5 Year73.5%73.5%-4.4%-10.0%60.7%42.7%

Price Volatility Vs. Market

How volatile is CASI Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CASI Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

3.76x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CASI's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CASI's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CASI is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CASI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CASI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CASI is overvalued based on its PB Ratio (3.8x) compared to the US Biotechs industry average (3.7x).


Next Steps

Future Growth

How is CASI Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-2.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CASI is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CASI is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CASI is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CASI's revenue (34.5% per year) is forecast to grow faster than the US market (8.8% per year).

High Growth Revenue: CASI's revenue (34.5% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CASI's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has CASI Pharmaceuticals performed over the past 5 years?

-31.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CASI is currently unprofitable.

Growing Profit Margin: CASI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CASI is unprofitable, and losses have increased over the past 5 years at a rate of -31.3% per year.

Accelerating Growth: Unable to compare CASI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CASI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: CASI has a negative Return on Equity (-49.8%), as it is currently unprofitable.


Next Steps

Financial Health

How is CASI Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: CASI's short term assets ($59.8M) exceed its short term liabilities ($7.5M).

Long Term Liabilities: CASI's short term assets ($59.8M) exceed its long term liabilities ($704.0K).


Debt to Equity History and Analysis

Debt Level: CASI is debt free.

Reducing Debt: CASI currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CASI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CASI has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 43.5% each year.


Next Steps

Dividend

What is CASI Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CASI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CASI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CASI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CASI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CASI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.2yrs

Average management tenure


CEO

Wei-Wu He (54yo)

1.17yrs

Tenure

US$9,410,827

Compensation

Dr. Wei-Wu He, Ph.D. serves as Chairman and Chief Executive Officer at CASI Pharmaceuticals, Inc since April 2, 2019 and served as its Executive Chairman from February 23, 2018 until April 2, 2019. Dr. He  ...


CEO Compensation Analysis

Compensation vs Market: Wei-Wu's total compensation ($USD9.41M) is above average for companies of similar size in the US market ($USD1.33M).

Compensation vs Earnings: Wei-Wu's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Wei-Wu He
Chairman & CEO1.17yrsUS$9.41m1.87% $4.9m
Wei Zhang
President & Interim Principal Financial Officer0.75yrUS$956.10kno data
Alexander Zukiwski
Chief Medical Officer3.17yrsUS$961.35kno data
Cynthia Hu
COO, General Counsel & Secretary11.5yrsUS$467.10kno data
Sara Capitelli
VP of Finance & Principal Accounting Officer9.42yrsUS$222.19kno data
James Goldschmidt
Senior Vice President of Business Development1.17yrsno datano data

2.2yrs

Average Tenure

54yo

Average Age

Experienced Management: CASI's management team is considered experienced (2.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Wei-Wu He
Chairman & CEO1.17yrsUS$9.41m1.87% $4.9m
Quan Zhou
Independent Director4yrsUS$139.00kno data
Ruijin Huang
Independent Director7.17yrsUS$144.85k0.00019% $502.4
Rajesh Shrotriya
Independent Director5.75yrsUS$125.60kno data
S. Eckhardt
Member of Scientific Advisory Board13.92yrsno datano data
Y. Wu
Independent Director7.17yrsUS$140.45kno data
Ghassan Abou-Alfa
Member of Clinical Advisory Board4.92yrsno datano data
Franklin Salisbury
Independent Director6yrsUS$140.45kno data
Robert Mayer
Member of Clinical Advisory Board4.92yrsno datano data

6.0yrs

Average Tenure

58yo

Average Age

Experienced Board: CASI's board of directors are considered experienced (6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CASI insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.4%.


Top Shareholders

Company Information

CASI Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CASI Pharmaceuticals, Inc.
  • Ticker: CASI
  • Exchange: NasdaqCM
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$264.397m
  • Shares outstanding: 100.91m
  • Website: https://www.casipharmaceuticals.com

Number of Employees


Location

  • CASI Pharmaceuticals, Inc.
  • 9620 Medical Center Drive
  • Suite 300
  • Rockville
  • Maryland
  • 20850
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CASINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJun 1996
ENMNDB (Deutsche Boerse AG)YesCommon StockDEEURJun 1996

Biography

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical products and various therapeutics in China, the United States, and internationally. The company’s product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprise CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma; CID-103, an anti-CD38 monoclonal antibody being for the treatment of patients with multiple myeloma; ZEVALIN, a CD20-directed radiotherapeutic antibody, to treat patients with NHL; and Thiotepa, a chemotherapeutic agent, which has multiple indications including use as a conditioning treatment for use prior to hematopoietic stem cell transplantation. In addition, the company offers MARQIBO, a microtubule inhibitor, approved by the FDA for the treatment of adult patients with Philadelphia chromosome-negative ALL; and Octreotide LAI formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumours, as well as developing a portfolio of 25 FDA-approved abbreviated new drug applications. It has licensing agreements with Black Belt Therapeutics Limited, Juventas Cell Therapy Ltd., and Pharmathen Global BV. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was founded in 1991 and is based in Rockville, Maryland. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 02:46
End of Day Share Price2020/06/04 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.